Eagle Pharmaceuticals Total Current Liabilities

The latest total current liabilities for EGRX is $87M as of June 2023. That compares with $110M in the prior-year period — down 20.5% year over year. Investors often review this figure alongside Eagle Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EGRX's total current liabilities moved from $110M to $87M — a 20.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eagle Pharmaceuticals's operating scale or balance-sheet position.

A total current liabilities figure of $87M for EGRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EGRX's total current liabilities ($87M), review year-over-year change from $110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Eagle Pharmaceuticals's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.